Bruch's Membrane Biomarker Detection for AMD Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively identify individuals with a propensity for inflammation that contributes to age-related macular degeneration (AMD), hindering early detection and appropriate treatment measures.
Innovation Solution
Detection of biomarkers 3-nitrotyrosine and nitro-A2E in Bruch's membrane using liquid chromatography-mass spectrometry (LC-MS) to diagnose AMD, assess inflammation, and monitor treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then AMD detection is possible, but early detection of inflammation propensity is not achieved
Solution Approach 1:
The patent detects biomarkers (3-nitrotyrosine and nitro-A2E) in Bruch's membrane before AMD fully develops, enabling preliminary identification of individuals with inflammation propensity. This early detection allows intervention before severe visual loss occurs, resolving the contradiction between current detection capabilities and early inflammation detection needs.
2Measurement precision
If biomarker detection in Bruch's membrane is implemented, then early AMD detection is achieved, but method complexity increases
Solution Approach 1:
The patent extracts and analyzes specific biomarkers (3-nitrotyrosine and nitro-A2E) from Bruch's membrane tissue samples using LC-MS technology. By focusing on these specific inflammatory biomarkers rather than attempting comprehensive analysis, the method achieves high detection accuracy while managing complexity through targeted extraction of key diagnostic indicators.
3Loss of time
If inflammation biomarkers are detected, then treatment timing is improved, but diagnostic capability worsens without specific biomarkers
Solution Approach 1:
The patent replaces conventional clinical examination methods with LC-MS mass spectrometry technology to detect inflammatory biomarkers. This substitution of analytical methodology enables precise quantification of 3-nitrotyrosine and nitro-A2E levels, providing both early detection capability and high measurement precision simultaneously, thus resolving the contradiction between early intervention timing and detection accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a non-invasive method for early detection of AMD, allows for timely intervention, and effectively monitors disease progression and treatment response by quantifying biomarkers in Bruch's membrane.
Implementation Method 1
Detection of biomarkers 3-nitrotyrosine and nitro-A2E in Bruch's membrane using liquid chromatography-mass spectrometry (LC-MS)
Implementation Method 2
Detection of biomarkers 3-nitrotyrosine and nitro-A2E in Bruch's membrane using liquid chromatography-mass spectrometry (LC-MS)
Data Source
AI summary
A method of diagnosing a patient with age-related macular degeneration (AMD), by detecting biomarkers in the patient's Bruch's membrane, and diagnosing the patient with AMD. A method of detecting the presence of AMD in a patient, by detecting biomarkers in the patient's Bruch's membrane. A method of detecting inflammation in a patient, by detecting biomarkers in the patient's Bruch's membrane. A method of determining the progression of AMD in a patient. A method of determining efficacy of a treatment for AMD in a patient. A method of determining the presence of AMD in an animal model. A kit for detecting the presence of disease in a patient, including an assay for biomarkers 3-nitrotyrosine and nitro-A2E. An assay of the biomarkers.